MED12 and leiomyoma: Recently Je et al. have published a mutational study of MED12 in 1862 samples, including leiomyomas, diverse carcinomas, leukemias, sarcomas and other stromal tumors, in which they observed only one malignant tumor with a MED12 mutation [27].